Cutera maintains a global footprint with direct sales teams in North America, Europe, and Japan, distributing products in over 65 countries. Key flagship products include AviClear (the first FDA-cleared energy device for acne treatment), Secret RF (fractional RF microneedling), and excel V+ (vascular and pigmentary treatment platform).
Cyborg Score Rationale
The company reported a net loss of $39M on $32.5M revenue (TTM basis) with a negative net profit margin of -120% and operating margin of -111%. Cutera announced voluntary delisting from Nasdaq (March 2025) and initiated a restructuring to reduce debt by nearly $400 million and raise $65 million.
Top Insights
The global dermatology devices market is projected to grow from $15.93 billion (2024) to $18.38 billion (2025) at 15.4% CAGR, providing substantial addressable market opportunity.
The company initiated a major debt restructuring (2025) to reduce debt by over 90% with 74% lender support, signaling critical financial distress.
Gross profit margin is only 5.58% on $1.8M gross profit against $32.5M revenue, indicating pricing pressure or high cost of goods sold.
Following restructuring, Cutera operates with a streamlined balance sheet on OTC markets while retaining strong technical innovation reputation.
Named Competitors
Candela Medical Devices — Aesthetic and surgical laser systems
Cynosure Aesthetic Systems — Energy-based aesthetic treatment devices
Synergetics USA — Ophthalmic and aesthetic surgical devices
Recent Developments
(March 2025) Voluntary delisting from Nasdaq announced with Form 25 filing
(February 2025) Initiated debt restructuring to eliminate ~$400M of liabilities and raise $65M in new capital
(2025) Transitioned to OTC markets following Nasdaq delisting
Open the full interactive Cutera Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.